Related references
Note: Only part of the references are listed.The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia
Xinyu Li et al.
HAEMATOLOGICA (2021)
Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma
Sarah Gooding et al.
BLOOD (2021)
Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma
Takuto Tachita et al.
CANCER SCIENCE (2020)
Cereblon harnesses Myc-dependent bioenergetics and activity of CD8(+) T lymphocytes
Rebecca S. Hesterberg et al.
BLOOD (2020)
The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research
Nathalie Percie du Sert et al.
PLOS BIOLOGY (2020)
Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma
Bachisio Ziccheddu et al.
BLOOD ADVANCES (2020)
Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia
Xinyu Li et al.
HAEMATOLOGICA (2019)
NKG2D and its ligands in cancer
Payal Dhar et al.
CURRENT OPINION IN IMMUNOLOGY (2018)
Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients
Laurens E. Franssen et al.
HAEMATOLOGICA (2018)
Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients
Laurens E. Franssen et al.
HAEMATOLOGICA (2018)
CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
Yasuhiro Oki et al.
HAEMATOLOGICA (2017)
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
Yasuhiro Oki et al.
HAEMATOLOGICA (2017)
Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab
Estefania Garcia-Guerrero et al.
BLOOD (2017)
Prospects for combining targeted and conventional cancer therapy with immunotherapy
Philip Gotwals et al.
NATURE REVIEWS CANCER (2017)
p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma
Teru Hideshima et al.
BLOOD (2017)
Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs
Takumi Ito et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2016)
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
Anas Younes et al.
LANCET ONCOLOGY (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma
Yoichi Imai et al.
JCI INSIGHT (2016)
Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma
Yasuhiro Oki et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
I. S. Nijhof et al.
LEUKEMIA (2015)
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Sagar Lonial et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
H. M. Lokhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
C. C. Bjorklund et al.
BLOOD CANCER JOURNAL (2015)
The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma
Cinzia Fionda et al.
ONCOTARGET (2015)
NKG2D Receptor and Its Ligands in Host Defense
Lewis L. Lanier
CANCER IMMUNOLOGY RESEARCH (2015)
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
Paul G. Richardson et al.
BLOOD (2014)
The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma
Andrew Spencer et al.
BLOOD (2014)
Molecular mechanisms of natural killer cell activation in response to cellular stress
C. J. Chan et al.
CELL DEATH AND DIFFERENTIATION (2014)
GSK-3-at the crossroads of cell death and survival
Ulrich Maurer et al.
JOURNAL OF CELL SCIENCE (2014)
New and emerging HDAC inhibitors for cancer treatment
Alison C. West et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
The anticancer effects of HDAC inhibitors require the immune system
Alison C. West et al.
ONCOIMMUNOLOGY (2014)
The 39th David A. Karnofsky Lecture: Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma
Kenneth C. Anderson
JOURNAL OF CLINICAL ONCOLOGY (2012)
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
A. Lopez-Girona et al.
LEUKEMIA (2012)
Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Michel Attal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Human NKG23-ligands: cell biology strategies to ensure immune recognition
Lola Fernandez-Messina et al.
FRONTIERS IN IMMUNOLOGY (2012)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar et al.
BLOOD (2011)
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Yuan Xiao Zhu et al.
BLOOD (2011)
Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide
Chad C. Bjorklund et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
MEDICAL PROGRESS Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Identification of a Primary Target of Thalidomide Teratogenicity
Takumi Ito et al.
SCIENCE (2010)
Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells
N. Kato et al.
LEUKEMIA (2007)
Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma
Hashem Younes et al.
CLINICAL CANCER RESEARCH (2007)
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib
George Mulligan et al.
BLOOD (2007)
The molecular classification of multiple myeloma
Fenghuang Zhan et al.
BLOOD (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Natural killer cells in breast cancer cell growth and metastasis in SCID mice
MZ Dewan et al.
BIOMEDICINE & PHARMACOTHERAPY (2005)
Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D Ligands by the histone deacetylase inhibitor sodium valproate
S Armeanu et al.
CANCER RESEARCH (2005)
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma
SA Schey et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells
S Lentzsch et al.
LEUKEMIA (2004)
GSK3 inhibitors: Development and therapeutic potential
P Cohen et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
PG Richardson et al.
BLOOD (2002)
Share Paper
